Anastasia Kovrizhina

Dr. Anastasia Kovrizhina

N.M. Kizhner Research and Educational Center, Tomsk Polytechnic University, Tomsk, Tomskaya Oblast’, Russia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ISIgor A. Schepetkin
Igor A. Schepetkin
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
Andrei PotapovAndrei Potapov
Andrei Potapov
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
VPVladislava V. Pavlova
Vladislava V. Pavlova
Mark QuinnMark Quinn
Mark Quinn

2 September 2016 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
ISIgor A. Schepetkin
Igor A. Schepetkin
SKSvetlana V. Kushnarenko
Svetlana V. Kushnarenko
GÖGulmira Özek
Gulmira Özek
LKLiliya N. Kirpotina
Liliya N. Kirpotina
PRPritam Sinha Roy
Pritam Sinha Roy
Mark QuinnMark Quinn
Mark Quinn

20 September 2021 in Molecules
Verified
Journal Article
Open access
PDF file
SLSerhii A. Liakhov
Serhii A. Liakhov
ISIgor Schepetkin
Igor Schepetkin
OKOlexander Karpenko
Olexander Karpenko
HDHanna I. Duma
Hanna I. Duma
NHNadiia M. Haidarzhy
Nadiia M. Haidarzhy
Mark QuinnMark Quinn
Mark Quinn
C-Jun N-terminal kinase (JNK) plays a central role in stress signaling pathways implicated in important pathological processes, including rheumatoid arthritis and ischemia-reperfusion injury. Therefore, inhibition of JNK is of interest for molecular targeted therapy to treat various diseases. We synthesized 13 derivatives of our reported JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime and evaluated their binding to the three JNK isoforms and their biological effects. Eight compounds exhibited submicromolar binding affinity for at least one JNK isoform. Most of these compounds also inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) activation and interleukin-6 (IL-6) production in human monocytic THP1-Blue cells and human MonoMac-6 cells, respectively. Selected compounds (4f and 4m) also inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. We conclude that indenoquinoxaline-based oximes can serve as specific small-molecule modulators for mechanistic studies of JNKs, as well as potential leads for the development of anti-inflammatory drugs.

16 June 2023 in Molecules
Verified
Journal Article
Open access
PDF file
ISIgor Schepetkin
Igor Schepetkin
OKOlexander Karpenko
Olexander Karpenko
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
LKLiliya N. Kirpotina
Liliya N. Kirpotina
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
Mark QuinnMark Quinn
Mark Quinn
The c-Jun N-terminal kinase (JNK) family includes three proteins (JNK1-3) that regulate many physiological processes, including cell proliferation and differentiation, cell survival, and inflammation. Because of emerging data suggesting that JNK3 may play an important role in neurodegenerative diseases, such as Alzheimer’s disease (AD) and Parkinson’s disease, as well as cancer pathogenesis, we sought to identify JNK inhibitors with increased selectivity for JNK3. A panel of 26 novel tryptanthrin-6-oxime analogs was synthesized and evaluated for JNK1-3 binding (Kd) and inhibition of cellular inflammatory responses. Compounds 4d (8-methoxyindolo[2,1-b]quinazolin-6,12-dione oxime) and 4e (8-phenylindolo[2,1-b]quinazolin-6,12-dione oxime) had high selectivity for JNK3 versus JNK1 and JNK2 and inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) transcriptional activity in THP-1Blue cells and interleukin-6 (IL-6) production by MonoMac-6 monocytic cells in the low micromolar range. Likewise, compounds 4d, 4e, and pan-JNK inhibitor 4h (9-methylindolo[2,1-b]quinazolin-6,12-dione oxime) decreased LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. Molecular modeling suggested modes of binding interaction of these compounds in the JNK3 catalytic site that were in agreement with the experimental data on JNK3 binding. Our results demonstrate the potential for developing anti-inflammatory drugs based on these nitrogen-containing heterocyclic systems with selectivity for JNK3.

12 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
ISIgor A. Schepetkin
Igor A. Schepetkin
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
KSKsenia S. Stankevich
Ksenia S. Stankevich
AKAndrei I. Khlebnikov
Andrei I. Khlebnikov
LKLiliya N. Kirpotina
Liliya N. Kirpotina
MCMatthew J. Cook
Matthew J. Cook
The c-Jun N-terminal kinase (JNK) family includes three proteins (JNK1-3) that regulate many physiological processes, including inflammatory responses, morphogenesis, cell proliferation, differentiation, survival, and cell death. Therefore, JNK represents an attractive target for therapeutic intervention. Herein, a panel of novel tryptanthrin oxime analogs were synthesized and evaluated for JNK1-3 binding (Kd) and inhibition of cellular inflammatory responses (IC50). Several compounds exhibited submicromolar JNK binding affinity, with the most potent inhibitor being 6-(acetoxyimino)indolo[2,1-b]quinazolin-12(6H)-one (1j), which demonstrated high JNK1-3 binding affinity (Kd = 340, 490, and 180 nM for JNK1, JNK2, and JNK3, respectively) and inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) transcription activity in THP-1Blue cells and interleukin-6 (IL-6) production in MonoMac-6 monocytic cells (IC50 = 0.8 and 1.7 μM, respectively). Compound 1j also inhibited LPS-induced production of several other proinflammatory cytokines, including IL-1α, IL-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF) in MonoMac-6 cells. Likewise, 1j inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. Molecular modeling suggested modes of binding interaction of selected compounds in the JNK3 catalytic site that were in agreement with the experimental JNK3 binding data. Our results demonstrate the potential for developing anti-inflammatory drugs based on these nitrogen-containing heterocyclic systems.

23 November 2021 in Molbank
Verified
Journal Article
Open access
PDF file
Anastasia KovrizhinaAnastasia Kovrizhina
Anastasia Kovrizhina
ESElizaveta Samorodova
Elizaveta Samorodova
Andrei KhlebnikovAndrei Khlebnikov
Andrei Khlebnikov
11H-Indeno[1,2-b]quinoxaline derivatives present an important type of nitrogen-containing heterocyclic compound that are useful intermediate products in organic synthesis and have potential pharmaceutical applications. A new 11H-indeno[1,2-b]quinoxalin-11-one-2-(4-ethylbenzylidene)hydrazone (compound 3) was synthesized. Compound 3 is the first example of an azine derivative based on the 11H-indeno[1,2-b]quinoxaline system. The Z,E-isomerism of compound 3 was investigated by DFT calculations. Bioavailability was evaluated in silico using ADME predictions. According to the ADME results, compound 3 is potentially highly bioavailable and has potential to be used for the treatment of neuroinflammation and ischemia–reperfusion injury.